The firm expects to complete enrolling the REVEAL trial, in which patients will receive the ASO, dubbed ION582, in 2026.

The $1.35 billion deal is expected to close in Q3 2025, giving RayzeBio rights to the radioligand, which is already undergoing Phase I testing as a diagnostic.